Clinofibrate

Research use only, not for human use.

Clinofibrate inhibits hydroxymethylglutaryl coenzyme A reductase (HMGCR) with IC50 of 0.47 mM.

Clinofibrate inhibits hydroxymethylglutaryl coenzyme A reductase (HMGCR) with IC50 of 0.47 mM, is a lipid-lowering agent used for controlling high cholesterol and triacylglyceride levels in the blood.(In Vivo):Clinofibrate administration (50 and 100 mg/kg/day, p.o.) significantly inhibits the increase in plasma fibrinogen level as well as serum- and VLDL-LDL-lipids. Clinofibrate significantly decreases the high plasma cholesterol level of atherosclerotic rats, which is 823±256 mg/dl, or about ten times that of control rats (85±11 mg/dl). On treatment with clinofibrate, the cholesterol level is reduced most in the very low density lipoprotein (VLDL) fraction. In rats which are refed either a fat-free diet or a 5% fat diet after a 2-day fast. clinofibrate at 30 mg/kg results in reductions of serum and liver triglyceride levels. Oral ingestion of S-8527 to normal rats for 7 days lowers serum triglycerides and cholesterol by about 27% at 1 mg/kg and 20% at 3 mg/kg, respectively. S-8527 at 3 mg/kg decreases liver triglyceride concentration by about 20%.

——

Clinofibrate administration (50 and 100 mg/kg/day, p.o.) significantly inhibits the increase in plasma fibrinogen level as well as serum- and VLDL-LDL-lipids. Clinofibrate significantly decreases the high plasma cholesterol level of atherosclerotic rats, which is 823±256 mg/dl, or about ten times that of control rats (85±11 mg/dl). On treatment with clinofibrate, the cholesterol level is reduced most in the very low density lipoprotein (VLDL) fraction. In rats which are refed either a fat-free diet or a 5% fat diet after a 2-day fast. clinofibrate at 30 mg/kg results in reductions of serum and liver triglyceride levels. Oral ingestion of S-8527 to normal rats for 7 days lowers serum triglycerides and cholesterol by about 27% at 1 mg/kg and 20% at 3 mg/kg, respectively. S-8527 at 3 mg/kg decreases liver triglyceride concentration by about 20%.

Clinofibrate | Lipoclin |

Metabolic Enzyme/Protease

HMGCR

HMGCR

Metabolic Disease

——

30299-08-2

468.58

C28H36O6

>98% (HPLC)

Ethanol: 94 mg/mL (200.6 mM); DMSO: 94 mg/mL (200.6 mM)

CCC(C)(OC1=CC=C(C2(C3=CC=C(OC(CC)(C(O)=O)C)C=C3)CCCCC2)C=C1)C(O)=O

2-[4-[1-[4-(2-Carboxybutan-2-yloxy)phenyl]cyclohexyl]phenoxy]-2-methylbutanoic acid

(-20℃)

With Ice Pack

≥ 2 years